1.845USD+3.07%Mkt Cap: 101.17M USDP/E: —Last update: 2026-05-26
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap101.17M USD
Enterprise Value-46.18M USD
Revenue (TTM)15.17M USD
Gross Profit8.01M USD
Net Income (TTM)-73.60M USD
Revenue/Share0.2680 USD
Last Price1.845 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees124
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.81
PEG—
EV/EBITDA0.67
EV/Revenue-3.04
P/S6.42
P/B0.38
EPS (TTM)-1.24
EPS (Forward)-0.98
52W Range
1.65026% of range2.410
52W High2.410 USD
52W Low1.650 USD
Profitability
Gross Margin49.67%
Oper. Margin-617.83%
EBITDA Margin0.00%
Profit Margin-456.60%
ROE-28.38%
ROA-24.86%
Growth
Revenue Growth-33.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-44.45M USD
CapEx (TTM)1.80M USD
FCF Margin—
FCF Yield—
Net Debt-143.64M USD
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity0.09
Current Ratio17.73
Quick Ratio16.69
Book Value/Sh4.612 USD
Cash/Share3.027 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.54.98M
Float40.55M
Insiders10.04%
Institutions51.02%
Short Interest
Short Ratio0.9d
Short % Float0.87%
Short % Out.0.78%
Shares Short427.62K
Short (prev mo.)732.58K
Technical
SMA 501.815 (+1.7%)
SMA 2001.961 (-5.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)419.27K
Avg Vol (10d)305.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—